Terms: = Breast cancer AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Clinical Outcome
809 results:
1. PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer.
Wang L; Guo W; Guo Z; Yu J; Tan J; Simons DL; Hu K; Liu X; Zhou Q; Zheng Y; Colt EA; Yim J; Waisman J; Lee PP
Cell Rep Med; 2024 Feb; 5(2):101420. PubMed ID: 38382468
[TBL] [Abstract] [Full Text] [Related]
2. Evidence of steady-state fibroblast subtypes in the normal human breast as cells-of-origin for perturbed-state fibroblasts in breast cancer.
Bagger MM; Sjölund J; Kim J; Kohler KT; Villadsen R; Jafari A; Kassem M; Pietras K; Rønnov-Jessen L; Petersen OW
Breast Cancer Res; 2024 Jan; 26(1):11. PubMed ID: 38229104
[TBL] [Abstract] [Full Text] [Related]
3. Two-Dimensional-PAGE Coupled with nLC-MS/MS-Based Identification of Differentially Expressed Proteins and Tumorigenic Pathways in MCF7 breast cancer Cells Transfected for JTB Protein Silencing.
Jayathirtha M; Jayaweera T; Whitham D; Sullivan I; Petre BA; Darie CC; Neagu AN
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005222
[TBL] [Abstract] [Full Text] [Related]
4. A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic breast cancer.
Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
Clin Cancer Res; 2024 Jan; 30(2):334-343. PubMed ID: 37992310
[TBL] [Abstract] [Full Text] [Related]
5. PTPN1 is a prognostic biomarker related to cancer immunity and drug sensitivity: from pan-cancer analysis to validation in breast cancer.
Zhao R; Chen S; Cui W; Xie C; Zhang A; Yang L; Dong H
Front Immunol; 2023; 14():1232047. PubMed ID: 37936713
[TBL] [Abstract] [Full Text] [Related]
6. Combination Organelle Mitochondrial Endoplasmic Reticulum Therapy (COMET) for Multidrug Resistant breast cancer.
Milane LS; Dolare S; Ren G; Amiji M
J Control Release; 2023 Nov; 363():435-451. PubMed ID: 37717658
[TBL] [Abstract] [Full Text] [Related]
7. Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate cancer.
Neeb A; Figueiredo I; Gurel B; Nava Rodrigues D; Rekowski J; Riisnaes R; Ferreira A; Miranda S; Crespo M; Westaby D; de Los Dolores Fenor de La Maza M; Guo C; Carmichael J; Grochot R; Tunariu N; Cato ACB; Plymate SR; de Bono JS; Sharp A
Lab Invest; 2023 Nov; 103(11):100245. PubMed ID: 37652207
[TBL] [Abstract] [Full Text] [Related]
8. Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial.
Cao J; Teng Y; Li H; Zhang L; Ouyang Q; Xie W; Pan Y; Song Z; Ling X; Wu X; Xu J; Li L; Ren L; Wang H; Zhou D; Luo J; Hu X
BMC Med; 2023 Aug; 21(1):300. PubMed ID: 37559142
[TBL] [Abstract] [Full Text] [Related]
9. High Level of GMFG Correlated to Poor clinical outcome and Promoted Cell Migration and Invasion through EMT Pathway in Triple-Negative breast cancer.
Zhao Y; Wei X; Li J; Diao Y; Shan C; Li W; Zhang S; Wu F
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372337
[TBL] [Abstract] [Full Text] [Related]
10. Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.
Takano EA; Younes MM; Meehan K; Spalding L; Yan M; Allan P; Fox SB; Redfern A; Clouston D; Giles GG; Christie EL; Anderson RL; Zethoven M; Phillips KA; Gorringe K; Britt KL
BMC Cancer; 2023 May; 23(1):459. PubMed ID: 37208678
[TBL] [Abstract] [Full Text] [Related]
11. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N; Fasching PA; Wuerstlein R; Degenhardt T; Lüftner D; Kates RE; Schumacher J; Räth P; Hoffmann O; Lorenz R; Decker T; Reinisch M; Göhler T; Staib P; Gluz O; Schinköthe T; Schmidt M;
Ann Oncol; 2023 Aug; 34(8):660-669. PubMed ID: 37201751
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer.
Yuan Y; Zhang S; Wang T; Bian L; Yan M; Yin Y; Song Y; Wen Y; Li J; Jiang Z
Chin Med J (Engl); 2023 Jun; 136(12):1459-1467. PubMed ID: 37101355
[TBL] [Abstract] [Full Text] [Related]
13. The role of p53 and ki67 in predicting clinical outcome in breast cancer patients.
Lalkota BP; Srinivasa BJ; Swamy MV; Hazarika D; Jeet BM; Jyothi K; Ghosh M; Sayeed SM; Nasiruddin M; Naik R
J Cancer Res Ther; 2023; 19(2):208-213. PubMed ID: 37006059
[TBL] [Abstract] [Full Text] [Related]
14. Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review.
Müller V; Bartsch R; Lin NU; Montemurro F; Pegram MD; Tolaney SM
Cancer Treat Rev; 2023 Apr; 115():102527. PubMed ID: 36893691
[TBL] [Abstract] [Full Text] [Related]
15. ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.
Song C; Kendi AT; Shim JY; Jung D; Kang PS; Lowe VJ; Lee S
Breast Cancer; 2023 May; 30(3):436-452. PubMed ID: 36859733
[TBL] [Abstract] [Full Text] [Related]
16. Identifying Biomarkers Using Support Vector Machine to Understand the Racial Disparity in Triple-Negative breast cancer.
Sahoo B; Pinnix Z; Sims S; Zelikovsky A
J Comput Biol; 2023 Apr; 30(4):502-517. PubMed ID: 36716280
[TBL] [Abstract] [Full Text] [Related]
17. Sea Cucumber Derived Triterpenoid Glycoside Frondoside A: A Potential Anti-Bladder cancer Drug.
Ru R; Chen G; Liang X; Cao X; Yuan L; Meng M
Nutrients; 2023 Jan; 15(2):. PubMed ID: 36678249
[TBL] [Abstract] [Full Text] [Related]
18. The Pan-cancer Multi-Omics Landscape of FOXO Family Relevant to clinical outcome and Drug Resistance.
Xie J; Zhang J; Tian W; Zou Y; Tang Y; Zheng S; Wong CW; Deng X; Wu S; Chen J; Mo Y; Xie X
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555288
[TBL] [Abstract] [Full Text] [Related]
19. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W
Front Immunol; 2022; 13():1058424. PubMed ID: 36544779
[TBL] [Abstract] [Full Text] [Related]
20. Muscle mass loss in breast cancer patients of reproductive age (≤ 45 years) undergoing neoadjuvant chemotherapy.
Rossi F; Lambertini M; Brunetti N; De Giorgis S; Razeti MG; Calabrese M; Tagliafico AS
Radiol Med; 2023 Jan; 128(1):49-57. PubMed ID: 36536266
[TBL] [Abstract] [Full Text] [Related]
[Next]
